IDEAYA Biosciences

IDYA · Nasdaq · United States

Share price · IDYA

$26.49-11.44 (-30.16%) 3M

close as of 2026-11-18 · 24h delayed · vol 1.5M (1.4x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when IDYA's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 17 Nov 2026-9.7%
  2. 29 Oct 2026-3.2%
  3. 26 Oct 2026-5.3%
  4. 22 Jun 2026+9.6%
  5. 9 Jun 2026-10.8%
  6. 8 Jun 2026+11.3%
  7. 13 Apr 2026+7.6%
  8. 23 Mar 2026-3.4%
  9. 3 Mar 2026+3.8%

    Nothing announced by IDYA that day or the session before.

  10. 19 Feb 2026+6.4%

Share of unusual movement by asset

For each asset, the share of IDYA's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Tuvutromstat
events and moves
911%
Darovasertib
events and moves
1810%
IDE892
events and moves
7shown from 8 days
IDE-161
events and moves
3shown from 8 days
IDE034
events and moves
3shown from 8 days
IDE574
events and moves
2shown from 8 days
Assets with fewer than 8 event days, together—5%
Other company news (earnings, financing, releases naming no asset)—30%
Sessions with no dated event—44%

Assets

(6 total)
6Total Assets
0Approved
1Phase 3 / Filed
5Phase 1–2 / Early
4Diseases
Quick filter:
Showing 6 of 6 assets
Target & Modality
Phase 3
Protein kinase C (PKC) (inhibitor)Small molecule
Uveal Melanoma
Phase 1/2
PARGSmall molecule
Ovarian Cancer
Phase 1/2
MAT2ASmall molecule
Non-Small Cell Lung CancerBladder Cancer
Phase 1
B7H3 and PTK7 (bispecific, co-expression-dependent internalization)Antibody–drug conjugate
Non-Small Cell Lung Cancer
Phase 1
KAT6/KAT7Small molecule
Non-Small Cell Lung Cancer
Phase 1
PRMT5Small molecule
Non-Small Cell Lung Cancer

Upcoming events

(6 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (3)
January 2027 (2)
DarovasertibPhase 2/3Metastatic Uveal Melanoma
Est. primary completion 2027-01-15 · NCT05987332 · CT.gov ↗
What to watch
DarovasertibPhase 1/2Metastatic Uveal Melanoma, Cutaneous Melanoma, Colorectal Cancer, Other Solid Tumors
Est. primary completion 2027-01-29 · NCT03947385 · CT.gov ↗
What to watch
April 2027 (1)
DarovasertibPhase 2Uveal Melanoma
Est. primary completion 2027-04-30 · NCT05907954 · CT.gov ↗
What to watch
2029 (1)
July 2029 (1)
IDE-161Phase 1/2Small-cell Lung Cancer, Neuroendocrine Carcinomas, Solid Tumor Show to Express DLL3
Est. primary completion 2029-07 · NCT07174583 · CT.gov ↗
What to watch
2030 (1)
October 2030 (1)
DarovasertibPhase 3Uveal Melanoma
Est. primary completion 2030-10 · NCT07015190 · CT.gov ↗
What to watch
2034 (1)
March 2034 (1)
DarovasertibPhase 3Uveal Melanoma
Est. primary completion 2034-03 · NCT07804186 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

1 June 2026Topline resultDarovasertibOptimUM-02 complete primary analysis data presented at ASCO
13 April 2026Topline resultDarovasertibOptimUM-02 Phase 2/3 (NCT05987332) met its primary endpoint: PFS by BICR
IDEAYA Biosciences · Source ↗

Financial reports

Quarterly & interim (17)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$10M$122M$263M+ $577M short-term inv.$126M-$93M operating cash flowreport ↗
View 16 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$8.9M$109M$274M+ $556M short-term inv.$112M-$88M operating cash flowreport ↗
2026-Q1$6.6M$96M$159M+ $514M short-term inv.$99M-$75M operating cash flowreport ↗
2025-Q4—$87M$114M+ $527M short-term inv.—-$91M operating cash flowreport ↗
2025-Q3$208M$83M$300M+ $488M short-term inv.—$142M operating cash flowreport ↗
2025-Q2—$74M$115M+ $555M short-term inv.$77M-$62M operating cash flowreport ↗
2025-Q1—$71M$131M+ $563M short-term inv.$72M-$60M operating cash flowreport ↗
2024-Q3$0$57M$401M+ $520M short-term inv.$52M-$49M operating cash flowreport ↗
2024-Q2$0$55M$184M+ $519M short-term inv.$53M-$33M operating cash flowreport ↗
2024-Q1$0$43M$109M+ $590M short-term inv.$40M-$44M operating cash flowreport ↗
2023-Q3$8.0M$34M$153M+ $317M short-term inv.$27M-$30M operating cash flowreport ↗
2023-Q2$3.5M$29M$104M+ $391M short-term inv.$28M-$33M operating cash flowreport ↗
2023-Q1$7.9M$28M$67M+ $272M short-term inv.$24M-$28M operating cash flowreport ↗
2022-Q3$30M$22M$102M+ $284M short-term inv.—-$24M operating cash flowreport ↗
2022-Q2$5.8M$23M$49M+ $220M short-term inv.$22M-$20M operating cash flowreport ↗
2022-Q1$11M$20M$55M+ $197M short-term inv.$14M-$20M operating cash flowreport ↗
2021-Q3$9.0M$16M$109M+ $156M short-term inv.$12M-$12M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$219M$315M$114M+ $527M short-term inv.$28M-$71M operating cash flowreport ↗

For FY2025, IDEAYA reported collaboration revenue of $218.71M, up 3024.4% YoY, with R&D expenses of $314.7M, up 6.8% YoY. The company ended the year with approximately $1.05 billion in cash, cash equivalents and marketable securities, and recorded a net loss of $113.7M, compared with a $274.5M net loss in 2024.

Topline PFS results from the Phase 2/3 OptimUM-02 trial of darovasertib plus crizotinib in 1L HLA*A2-negative metastatic uveal melanoma are expected by approximately the last week of March, with 130 PFS events confirmed by BICR. Darovasertib is anticipated to enter three randomized Phase 3 trials across uveal melanoma settings by H1 '26, and IDE849 registrational study initiation with preliminary Phase 1 data is targeted for end of 2026. GSK notified IDEAYA of termination of the Werner Helicase and Pol Theta collaboration, with program transfer back to IDEAYA, while the company received a $210.0M upfront payment from Servier during 2025. Cash is expected to fund operations into 2030.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$7.0M$295M$85M+ $592M short-term inv.$69M-$248M operating cash flowreport ↗
2023-FY$23M$130M$158M+ $368M short-term inv.$28M-$115M operating cash flowreport ↗
2022-FY$51M$90M$69M+ $296M short-term inv.$15M-$87M operating cash flowreport ↗
2021-FY$28M$58M$92M+ $155M short-term inv.$12M-$56M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 1 purchase ($1.6M), 3 sales ($1.4M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-10-06Hata Yujiro S · director, President and CEOOption exercise26,338$4.31$114KForm 4
2026-10-06Hata Yujiro S · director, President and CEOOpen-market sale25,538$37.39$955KForm 4
2026-10-06Hata Yujiro S · director, President and CEOOpen-market sale800$38.26$31KForm 4
2026-10-06Hata Yujiro S · director, President and CEOOption exercise (derivative)26,338——Form 4
2026-07-07Ruiz Briseno Andres · Chief Accounting OfficerOption exercise9,550$12.86$123KForm 4
2026-07-07Ruiz Briseno Andres · Chief Accounting OfficerOpen-market sale9,550$40.01$382KForm 4
2026-07-07Ruiz Briseno Andres · Chief Accounting OfficerOption exercise (derivative)9,550——Form 4
2026-06-16Hampton Malcolm Garret · directorAward / grant (derivative)20,000——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 252 reporting institutions held 94.7M shares ($3.1B, 97.9% of shares outstanding).

#InstitutionSharesValue
1FMR LLC13,172,103$438.9M
2BlackRock, Inc.8,442,133$281.3M
3JANUS HENDERSON GROUP PLC7,265,253$242.0M
4Capital Research Global Investors5,163,543$172.0M
5BAKER BROS. ADVISORS LP3,946,515$131.5M
6STATE STREET CORP3,781,167$126.0M
7VANGUARD CAPITAL MANAGEMENT LLC3,732,422$124.4M
8Logos Global Management LP3,450,000$115.0M
9FEDERATED HERMES, INC.2,987,107$99.5M
10ADAGE CAPITAL PARTNERS GP, L.L.C.2,823,500$94.1M
11Fiera Capital Corp2,527,076$84.2M
12GEODE CAPITAL MANAGEMENT, LLC2,500,724$83.3M
13MORGAN STANLEY1,860,453$62.0M
14GOLDMAN SACHS GROUP INC1,655,617$55.2M
15DEERFIELD MANAGEMENT COMPANY, L.P.1,530,008$51.0M